Mount Sinai Health System and BronxCare Health System open cancer facility

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mount Sinai Health System and BronxCare Health System have launched BronxCare Mount Sinai Comprehensive Cancer Care—a new comprehensive cancer facility in the Bronx. 

The 10,000 square f00t space houses medical oncology, surgical oncology, and support services, and an expanded treatment area with dedicated chemotherapy and immunotherapy infusion suites. 

Kevin R. Jain, section chief of medical oncology and hematology at BronxCare Health System, will direct the center. 

The facility’s staff includes five medical oncologists and hematologists, five general surgeons, two surgical oncologists, two thoracic surgeons, two radiation oncologists, two neurosurgeons, four urologists, one social worker, two oncology-specialized ENT surgeons, an oncology-certified nursing team, two board-certified oncology pharmacists, an oncology pharmacy residency training program, and a team of administrative and support staff.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login